Attached files
| file | filename |
|---|---|
| 10-Q - FORM 10-Q - CNS Pharmaceuticals, Inc. | cns_10q-033120.htm |
| EX-31.1 - CERTIFICATION BY CHIEF EXECUTIVE OFFICER - CNS Pharmaceuticals, Inc. | cns_10q-ex3101.htm |
| EX-32.1 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER - CNS Pharmaceuticals, Inc. | cns_10q-ex3201.htm |
| EX-31.2 - CERTIFICATION BY CHIEF FINANCIAL OFFICER - CNS Pharmaceuticals, Inc. | cns_10q-ex3102.htm |
| EX-3.1 - AMENDED AND RESTATED ARTICLES OF INCORPORATION - CNS Pharmaceuticals, Inc. | cns_10q-ex0301.htm |
Exhibit 32.2
CERTIFICATION OF CHIEF EXECUTIVE OFFICER
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)
Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), the undersigned officer of CNS Pharmaceuticals, Inc., a Nevada corporation (the "Company"), does hereby certify, to such officer’s knowledge, that:
The quarterly report on Form 10-Q for the quarter ended March 31, 2020 (the "Form 10-Q") of the Company fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended and information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.
May 15, 2020
By: /s/ Christopher Downs
Christopher Downs
Chief Financial Officer
(Principal financial and accounting officer)